Partner Content Partner Content This Week's Spotlight Features GSK and Advanced Cell Diagnos... RNA Therapeutics Feb 2018
Partner Content Partner Content STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics STORM Therapeutics Exclusive Speaker Interview
Partner Content Partner Content STORM Therapeutics Announces Publication in Nature on RNA Ep... RNA Therapeutics
Partner Content Partner Content The first patient to be injected with an RNA based anti-canc... RNA Therapeutics
Partner Content Partner Content Topics Presented this February 2018 at RNA Therapeutics RNA Therapeutics
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.